Unlock Cancer’s Secrets: TCT BioPharm Joins Forces to Harness the Power of Gamma Delta T Cells

Exploring the role of gamma-delta T cells in oncological settings is an exciting area of research with potentially groundbreaking implications. By devoting our attention to this topic, we can gain a greater insight into how these cells can be used to fight cancer and other diseases. With continued research and effort, we may be able to unlock the secrets of how gamma-delta T cells can be used to combat the devastating effects of cancer.

TC BioPharm (Holdings) PLC, a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer treatment, today announced an exciting strategic collaboration with The MD Anderson Cancer Center to help unlock the potential of gamma-delta T cells for cancer treatment. With this collaboration, the two partners aim to gain a deeper understanding of how gamma-delta T cells work in oncology settings and help to develop more effective and targeted therapies for cancer patients.

In an exciting three-year collaboration, MD Anderson Cancer Center and TC BioPharm have joined forces to explore the potential of gamma-delta T cell therapies. Combining MD Anderson’s powerful clinical trial infrastructure and immunotherapy platform with TC BioPharm’s clinical data, the research teams will conduct preclinical and clinical studies to better understand the behavior of these cells in patients. To guide their efforts, the collaborators have formed a six-person steering committee to develop the data set and subsequent assays for each study. Together, they hope to unlock the potential of gamma-delta T cell therapies and revolutionize cancer treatment.

Unlock the power of immunotherapy and uncover detailed insights into the behavior of gamma-delta T cells with MD Anderson’s comprehensive immunoprofiling platform. Led by internationally renowned experts in immunology and genitourinary medical oncology, Padmanee Sharma, M.D., Ph.D. and James Allison, Ph.D., this innovative platform enables correlative studies on clinical samples to inform and improve patient outcomes.

By gaining a more comprehensive understanding of what happens to patients during gamma delta T cell therapies, TC Biopharm can create more effective studies, and pave the way for targeted cancer treatments for blood cancers and solid tumors. With this expanded knowledge, the possibilities for future treatments are endless.

We are delighted to be joining forces with MD Anderson to explore the potential of gamma delta T cells and how they can be harnessed to create new treatments using our OmnImmune platform therapy. This collaboration is a testament to our shared commitment to accelerating the discovery and development of revolutionary cell therapies, and it also showcases TC Biopharm’s cutting-edge experience in the field of gamma delta T cells.

About TC BioPharm (Holdings) PLC

TC BioPharm is a revolutionary clinical-stage biopharmaceutical company dedicated to developing groundbreaking gamma-delta T cell therapies for the treatment of cancer. With promising human efficacy data in acute myeloid leukemia, these cutting-edge therapies harness the power of gamma-delta T cells; an immune cell that combines the best of both the innate and adaptive immune systems. Using an allogeneic approach, TC BioPharm is able to identify, target, and eradicate both liquid and solid tumors in cancer, offering patients a new and improved pathway to recovery.

TC BioPharm is at the forefront of developing revolutionary gamma-delta T cell therapies, having conducted the world’s first Phase II/pivotal clinical studies in oncology. Currently, the company is running two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for OmnImmune┬« in the treatment of acute myeloid leukemia. What’s more, TC BioPharm has a robust pipeline of future indications in solid tumors, as well as a strong IP/patent portfolio in the use of CARs with gamma-delta T cells. To ensure quality and cost control, the company also owns its own manufacturing facility.

Forward Looking Statements

Looking to the future, this press release may contain statements forecasting upcoming events. However, these predictions are subject to a variety of unpredictable factors that could significantly affect the results. Our current beliefs may not be accurate, and we cannot guarantee that the results will be as expected. Additionally, the link to TC BioPharm’s website is provided for convenience only, and the information contained on the website is not part of this press release.

Leave a Comment